Alliancebernstein L.P. Has $306.37 Million Position in Boston Scientific Corporation $BSX

Key Points

• Alliancebernstein L.P. increased its stake in Boston Scientific Corporation by 64.3%, owning 3,036,935 shares worth approximately $306.37 million at the end of the first quarter.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, exceeding the consensus estimate of $0.72, with a year-over-year revenue increase of 22.8%.
• Analysts maintain optimism with Boston Scientific receiving multiple upgrades, including a price target increase from $119 to $125 from Citigroup.

Alliancebernstein L.P. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 64.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,036,935 shares of the medical equipment provider's stock after buying an additional 1,189,016 shares during the quarter. Alliancebernstein L.P. owned about 0.21% of Boston Scientific worth $306,366,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG lifted its position in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE boosted its stake in shares of Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after buying an additional 1,439 shares during the period. Aptus Capital Advisors LLC grew its holdings in shares of Boston Scientific by 17.3% during the 4th quarter. Aptus Capital Advisors LLC now owns 11,692 shares of the medical equipment provider's stock valued at $1,044,000 after acquiring an additional 1,723 shares in the last quarter. Finally, Algert Global LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth $297,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BSX shares. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Needham & Company LLC reiterated a "buy" rating and issued a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Wells Fargo & Company increased their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $117.79.

Boston Scientific Stock Performance

Shares of BSX traded up $0.92 during trading hours on Monday, reaching $108.14. 7,421,052 shares of the company traded hands, compared to its average volume of 7,464,307. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $108.94. The stock has a market cap of $160.23 billion, a P/E ratio of 64.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The stock's fifty day moving average is $104.77 and its 200 day moving average is $102.15. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.